Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265 · clinicaltrials.gov ↗

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma
PSA Progression
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

OTHER: Cytology Specimen Collection Procedure
DRUG: Enzalutamide
OTHER: Laboratory Biomarker Analysis

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]